Keyword: Celgene

RBC Capital Markets investors picked an oncology expert as their top candidate to replace Gilead CEO John Milligan.

Celgene is extracting volume-driven sales growth as the entire industry has come under scrutiny for its pricing.

Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon.

Agios Pharmaceuticals has scored its first FDA nod for a wholly-owned medicine, Tibsovo.

A patent ruling for Novartis will give Celgene time to secure FDA approval for its Gilenya rival and persuade physicians that it's a safer MS pill.

Though Trump convinced Pfizer to delay its planned price increases, Celgene, Roche and Novo have gone through with their own increases in July.

J&J and Allergan are among the pharma companies mulling both acquisitions and selloffs, signaling that the M&A boom will continue through 2018.

Celgene CEO Mark Alles pledged to control price increases, but it's unclear whether the vow applies to cancer blockbuster Revlimid.

AbbVie has stored dozens of Humira patents in Bermuda, allowing it to lower its corporate tax rate, according to Reuters.

Another week, another dismal pharma trust and reputation poll. This time, the poll comes from the Reputation Institute.